to encourage and boost exports. Therefore, the question of payment of compensation, or amendment of the Central Sales Tax Act, 1956 as suggested by the Government of Kerala, does not arise.

Objectives functions of Biotech Consortium India Limited

1159. SHRIMATI PRATIBHA SINGH:
SHRI ASHOK NATH VERMA:

Will the Minister of FINANCE be pleased to state:

(a) what are the objective and functions, Financial|Promotion Services of Biotech Consortium India Limited jointly promoted by IDBI, IFCI, ICICI and UTI;

(b) what forms of financial assistance are being offered by the organisation particularly to small sector units and the name and addresses of the beneficiaries and the amount sanctioned, project-wise;

(c) what are the norms and terms laid down by the Biotech Consortium for financial assistance for such Venture|Projects in small sector or otherwise; and

(d) what are the names and addresses of the authorised offices of the Company, region-wise?

THE MINISTER OF STATE IN THE MINISTRY OF FINANCE (SHRI DALBIR SNGH): (a) The Industrial Development Bank of India (IDBI) has reported that the objective of the Biotech Consortium India Ltd. (BCIL) is to catalyse the interaction between industry and research development institutes, including the universities, so as to convert such interactions, concepts and ideas in Biotechnology into products and processe and to take such goods and services to the market place through industry.

The major functions of BCIL are to assist in the identification of need-based technologies. the preparation of pre-feasibility reports as also detailed project reports; the development of prototypes and establishment of pilot plants; to facilitate commercialisation of Bioteenology process and products by industry; and to provide information services.

The major financial and promotional services proposed to be offered by BCL would include counselling to individual firms or other agencies; financial and other assistance for innovation, development, commercialisation and marketing of biotechnology in particular; and long term financial assistance to industrial concerns utition is not acceptable. Further, he lising biotechnology for the purpose of industrial development. It would also assist in sale or disposal of the know-how generated.

(b) The Consortium provides long term finance to prospective entrepreneurs in their efforts to commercialise technologies developed in the laboratory|pilot plant scale in universities, R&D institutions and other research bodies. The financial assistance is provided by way of loans for the preparation of pre-feasibility reports (upto Rs. 1 lac) detailed project reports (upto Rs. 3 lac) and for setting up of pilot plants prior to commercialisation (Rs. 20 lacs). Such projects would generally be in the small|medium sector.

The addresses of the beneficiaries and assistance sanctioned are as under:

Beneficiary	Assistance Sanctioned
1. Tamil Nadu G.D. Naidu Agricultural University, Coimbatore & Madurai.	Rs. 10.5 lakhs for each of these locations.
2. Bangalore Genet Pvt. Ltd. Bangalore.	Rs. 90,000/-

(c) For preparation of pre-feasibility reports, assistance is provided upto Rs. 1 lakh and promoters contribution expected is a minimum of 10 per cent. For the preparation of detailed project reports, a loan of Rs. 3 lakhs is provided with a minimum promoters contribution of 30 per cent. For conducting pilot plant studies prior to commercial launch of an innovative venture, loans upto Rs. 20 lakhs are provided with a minimum promoters' contribution of 30 per cent which could be relaxed to about 20 per cent in case of universities/ academic institutions depending on the merits of the case.

(d) Activities of Biotech Consortium India Ltd., are being conducted only from its registered office in New Delhi at the following address:

BIOTECH CONSORTIUM INDIA LTD.,
G-6, N.D.S.E.-I,
NEW DELHI-110049.

आई० डी० पी० एल० द्वारा निर्मित घटिया दवाइयां

1160. **डा० अबरार अहमद** : क्या **स्वास्थ्य और परिवार कल्याण** मंत्री यह बताने की कृपा करेंगे कि :

(क) इंडियन ड्रग्स एण्ड फार्मेस्यूटिकल लिमिटेड द्वारा निर्मित ऐसी दवाइयों के नाम क्या हैं, जिन्हें पिछले पांच वर्षों के दौरान घटिया पाया गया था ;

(ख) क्या सरकार ने इसकी जांच के आदेश दिए हैं ; और

(ग) यदि हां, तो उसका ब्यौरा क्या है और इसमें किन-किन व्यक्तियों को दोषी पाया गया ?

स्वास्थ्य और परिवार कल्याण मंत्रालय में राज्य मंत्री (श्रीमती डी० के० तारा देवी सिद्धार्थ) : (क) इंडियन ड्रग्स एण्ड फार्मेस्यूटिकल्स लिमिटेड (आई०डी०पी०एल०) द्वारा निर्मित औषधों के नाम, जिन्हें पिछले पांच वर्षों में दिए गए परीक्षण के दौरान घटिया पाया गया, घटिया पाये जाने के कारणों सहित, उपलब्ध सूचना के अनुसार विवरण में दिए गए हैं ।

(ख) और (ग) जबकि कुछ मामलों में राज्य लाइसेंसिंग प्राधिकारियों ने इंडियन ड्रग्स एण्ड फार्मेस्यूटिकल लिमिटेड (आई० डी० पी० एल०) को कारण बताओ नोटिस दिया है स्वास्थ्य सेवा महानिदेशालय ने राज्य लाइसेंसिंग प्राधिकारियों से ऐसे मामलों में उनके द्वारा की गई कार्रवाई का ब्यौरा भेजने को कहा है ।

विवरण

मैसर्स आई० डी० पी० एल. गुडगांव (हरियाणा), द्वारा निर्मित और गत पांच वर्षों के दौरान घटिया किस्म की पाई गई औषधों की संख्या

क्रम सं०	औषधि का नाम और बैच संख्या	वर्ष	घटिया पाए जाने के कारण
1	2		3
1.	सल्फासेटामाइड आई ड्राप बैच नं० एस सी—09	1985	विजातीय कण पाए गए
2.	क्लोरेमेफनिकोल पॉम	—तदेव—	घोल एक रूप नहीं है और पिंड शामिल हैं